Anavex Life Sciences' blarcamesine demonstrates sustained cognitive and functional benefits in early Alzheimer's patients over three years of continuous oral treatment.
Anavex Life Sciences is developing Anavex 2-73, a small molecule targeting the sigma-1 receptor, for neurodegenerative and neurodevelopmental disorders.
Anavex Life Sciences reports positive preliminary results from its Phase 2 trial of ANAVEX3-71 in schizophrenia, showing dose-dependent effects on EEG biomarkers.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.